Cell Therapeutics, Inc. – Amended and Restated Exclusive License and Collaboration Agreement (May 3rd, 2017)
LES LABORATOIRES SERVIER, a company duly organized and existing under the laws of France, having offices and principal place of business at 50 Rue Carnot, 92284 Suresnes Cedex, France
Cell Therapeutics, Inc. – October 19, 2016 Re: Side Letter #2 on Term Sheet Timing Issues Dear Mr. Plunkett: (October 24th, 2016)
Pursuant to Section 16.7 of the Development, Commercialization and License Agreement, dated November 14, 2013, as previously amended by that certain letter agreement re Side Letter on Term Sheet Timing Issues, dated September 19, 2016, between CTI BioPharma Corp. and Baxalta US Inc., as well as all other previous amendments (the "DCLA"), this letter, for good and valuable consideration, further amends that agreement.
Cell Therapeutics, Inc. – [Shire Letterhead] (September 19th, 2016)
Pursuant to Section 16.7 of the Development, Commercialization and License Agreement, dated November 14, 2013, as amended (the "DCLA"), this letter, for good and valuable consideration, amends that agreement. The parties hereby agree that, notwithstanding anything to the contrary in the DCLA, if, within thirty (30) days after the date hereof, the parties are unable to reach a final signed agreement reflecting the terms contained within the nonbinding Term Sheet agreed to between the parties as of September 19, 2016, then for purposes of computing any applicable termination period(s) and deadlines under Section 15.2 of the DCLA, September 13, 2016 shall be deemed the effective date of the notice of termination of the DCLA by Baxalta (but for the avoidance of doubt shall not be the effective date of the termination of the DCLA) and the termination notice of September 13, 2016 shall be revived.
Cell Therapeutics, Inc. – Contract (October 31st, 2014)
Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Cell Therapeutics, Inc. – Severance Agreement (March 22nd, 2013)
This SEVERANCE AGREEMENT (the Agreement) is entered into by and between Cell Therapeutics, Inc., a Washington corporation (CTI or the Company), and Matthew Plunkett (the Executive).
Cell Therapeutics, Inc. – [Cell Therapeutics, Inc. Letterhead] (February 28th, 2013)
This position is determined to be exempt from overtime under federal and state law. Your base salary will be payable on a semi-monthly basis at the annual rate of $325,000. Performance is reviewed on an annual basis. As an employee, you will participate in the benefits program offered by the Company, including vacation and sick leave and the group medical and life insurance plans provided. Vacation will accrue at 3 weeks per year (5 hours per payroll period) starting on your hire date and you will receive 5 floating/personal holidays per calendar year.